Trial reportBMC pulmonary medicine2013
A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan.
Trial report in BMC pulmonary medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review.Current oncology (Toronto, Ont.) · 2024Pooled it
- Prevalence and Prognostic Significance of Hyponatremia in Patients With Lung Cancer: Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Evidence for the use of demeclocycline in the treatment of hyponatraemia secondary to SIADH: a systematic review.International journal of clinical practice · 2015Pooled it
- Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study.Japanese journal of clinical oncology · 2021Trial
- Diagnostic assistance provided by a pharmacist for the syndrome of inappropriate antidiuretic hormone secretion caused by carboplatin plus nab-paclitaxel chemotherapy in an elderly patient with lung cancer: a case report.Journal of pharmaceutical health care and sciences · 2025Article
- An unyielding challenge for refractory hyponatremia in neuroendocrine cervix carcinoma: a case report.Frontiers in endocrinology · 2025Article
- Article
- Symptomatic syndrome of inappropriate anti-diuretic hormone as a rare early presentation of primary thymic carcinoma: a case report.Journal of surgical case reports · 2024Article
- Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.EClinicalMedicine · 2023Article
- Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer.Endocrine oncology (Bristol, England) · 2022Review
- Mechanisms and management of edema in pediatric nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2021Review
- The role of tolvaptan in managing hyponatremia in small cell lung cancer patients with SIADH: a retrospective study of 23 cases.Translational cancer research · 2021Article
- A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia.Translational lung cancer research · 2020Review
- Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan.European journal of clinical pharmacology · 2020Article
- Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Optimal Management.Therapeutics and clinical risk management · 2020Review
- Tolvaptan corrects hyponatremia and relieves the burden of fluid/dietary restriction and hospitalization in hyponatremic patients with terminal lung cancer: a report of two cases.CEN case reports · 2019Article
- Small-cell lung cancer with Mallory-Weiss syndrome as the prominent manifestation.International journal of clinical and experimental pathology · 2019Article
- Practical issues for the management of hyponatremia in oncology.Endocrine · 2018Review
- Successful treatment by tolvaptan of the syndrome of inappropriate antidiuretic hormone secretion that may be associated with chemotherapy-induced tumour lysis in a patient with small-cell lung carcinoma.Respirology case reports · 2018Article
- Beyond the Dual Paraneoplastic Syndromes of Small-Cell Lung Cancer with ADH and ACTH Secretion: A Case Report with Literature Review and Future Implications.Case reports in oncological medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyponatremia based on syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH) is observed in up to 15% of patients with small cell lung cancer (SCLC). The electrolyte imbalance is associated with a high morbidity and mortality and often delays appropriate treatment. Management of hyponatremia proved to be challenging until new vasopressin-2 receptor antagonists such as tolvaptan became available. This is the first report which presents a prospective case series with an efficient management of hyponatremia including tolvaptan in ten patients with SCLC and severe SIADH (plasma sodium < 125 mmol/l).
methodsTen patients with SCLC and severe SIADH were followed after the onset of clinical symptoms of SIADH. Patients were chosen on the basis of histological proven diagnosis of SCLC and the clinical picture of a neurocognitive deficit caused by SIADH-related hyponatremia. All patient data were monitored for clinical improvement based on ECOG status, commencement of chemotherapy and correction of sodium levels.
resultsThe treatment followed a diagnostic and treatment algorithm and lead to a rapid and efficient correction of both clinical symptoms and plasma sodium level.
conclusionsBased on this algorithm all patients started chemotherapy in time. Subsequently, the treatment with tolvaptan lead to an improvement of the ECOG-performance status. In addition, all patients benefit from the effective management of SIADH which omitted prolonged hospital stays and non-elective hospitalizations due to an unstable clinical condition due to severe hyponatremia. These observations add new insight to management of SIADH in thoracic oncology and are of interest for specialists in oncology, endocrinology and pulmonary medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.